{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:17:51Z","timestamp":1790781471941,"version":"4.1.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00428-9","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:22:26Z","timestamp":1774524146000},"page":"449-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Meral","family":"Beksac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Samra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abduljalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"AAL Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Besisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guldane Cengi\u0307z","family":"Seval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Elghandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcner Hayri","family":"\u00d6zsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Marashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6m\u00fcr G\u00f6kmen","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba Yaseen Ibrahim","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumika","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mouro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Phansalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"5","key":"428_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et\u00a0al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"12","key":"428_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et\u00a0al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"428_CR3","unstructured":"Ferlay J EM, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: cancer today (version 1.1). 2024. https:\/\/gco.iarc.who.int\/today. Accessed 28 Nov 2024."},{"issue":"1","key":"428_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19\u201337. https:\/\/doi.org\/10.1007\/s40265-017-0841-y.","journal-title":"Drugs"},{"issue":"3","key":"428_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et\u00a0al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"428_CR6","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et\u00a0al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","journal-title":"Ann Oncol"},{"issue":"1","key":"428_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et\u00a0al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21(1):606. https:\/\/doi.org\/10.1186\/s12885-021-08280-y.","journal-title":"BMC Cancer"},{"issue":"2","key":"428_CR8","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347. https:\/\/doi.org\/10.3390\/curroncol30020179.","journal-title":"Curr Oncol"},{"issue":"6","key":"428_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5","volume":"12","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et\u00a0al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98. https:\/\/doi.org\/10.1038\/s41408-022-00695-5.","journal-title":"Blood Cancer J"},{"issue":"3","key":"428_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.16124","volume":"188","author":"VT de Moraes Hungria","year":"2020","unstructured":"de Moraes Hungria VT, Mart\u00ednez-Ba\u00f1os DM, Pe\u00f1afiel CR, Miguel CE, Vela-Ojeda J, Remaggi G, et\u00a0al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016. Brit J Haematol. 2020;188(3):383\u201393. https:\/\/doi.org\/10.1111\/bjh.16124.","journal-title":"Brit J Haematol"},{"issue":"8","key":"428_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","volume":"21","author":"P Neri","year":"2024","unstructured":"Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024;21(8):590\u2013609. https:\/\/doi.org\/10.1038\/s41571-024-00913-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"428_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341430","volume":"2015","author":"WC Yang","year":"2015","unstructured":"Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430. https:\/\/doi.org\/10.1155\/2015\/341430.","journal-title":"Biomed Res Int"},{"issue":"1","key":"428_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/13696998.2020.1867469","volume":"24","author":"TH Steinmetz","year":"2021","unstructured":"Steinmetz TH, Singh M, Lebioda A, Fink L, Schoehl M, Rieth A, et\u00a0al. Healthcare resource utilization and costs among patients with relapsed and\/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. J Med Econ. 2021;24(1):114\u201322. https:\/\/doi.org\/10.1080\/13696998.2020.1867469.","journal-title":"J Med Econ"},{"key":"428_CR14","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1097\/01.HS9.0000852292.38263.b8","volume":"6","author":"E Crusoe","year":"2022","unstructured":"Crusoe E, Ribeiro G, Zanella K, Perobelli L, Filho JCS, Magalhaes R, et\u00a0al. Multiple myeloma Brazilian register- how about the transplant eligible patients? HemaSphere. 2022;6:3449\u201350. https:\/\/doi.org\/10.1097\/01.HS9.0000852292.38263.b8.","journal-title":"HemaSphere"},{"issue":"4","key":"428_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","volume":"98","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, et\u00a0al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941\u20139. https:\/\/doi.org\/10.1007\/s00277-019-03602-4.","journal-title":"Ann Hematol"},{"issue":"4","key":"428_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1053\/j.seminhematol.2023.07.001","volume":"60","author":"MJ Mela Osorio","year":"2023","unstructured":"Mela Osorio MJ, Pavlovsky C, Pavlovsky MA. Inequalities in access to treatment in Argentina: differences in management of CLL and multiple myeloma? Semin Hematol. 2023;60(4):209\u201314. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.07.001.","journal-title":"Semin Hematol"},{"issue":"4","key":"428_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.htct.2024.02.024","volume":"46","author":"C Pe\u00f1a","year":"2024","unstructured":"Pe\u00f1a C, Graffigna P, Russo M, Forray E, Bustamante P. Improved overall survival of transplant eligible newly diagnosed multiple myeloma patients in a Chilean public center. How did we achieve it? Hematol Transfus Cell Ther. 2024;46(4):575\u20136. https:\/\/doi.org\/10.1016\/j.htct.2024.02.024.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"428_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4067\/s0034-98872022000300331","volume":"150","author":"F Samaniego","year":"2022","unstructured":"Samaniego F, Bull L, Gonz\u00e1lez N, Araos D, Rojas H, Donoso J, et\u00a0al. The impact of novel drugs on the survival of patients with multiple myeloma in two Chilean centers. Rev Med Chil. 2022;150(3):331\u20138. https:\/\/doi.org\/10.4067\/s0034-98872022000300331.","journal-title":"Rev Med Chil"},{"issue":"9","key":"428_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et\u00a0al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2128.","journal-title":"JAMA Oncol"},{"issue":"5","key":"428_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","volume":"117","author":"A Mafra","year":"2024","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F, et\u00a0al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 2024;117(5):907\u201314. https:\/\/doi.org\/10.1093\/jnci\/djae321.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"428_CR21","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, et\u00a0al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X.","journal-title":"Lancet Haematol"},{"issue":"4","key":"428_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/03007995.2025.2502125","volume":"41","author":"A Alhuraiji","year":"2025","unstructured":"Alhuraiji A, Lal A, Al Mehairi A, Alam A, Mudawi D, Khan F, et\u00a0al. Epidemiology and approaches for management of relapsed and refractory multiple myeloma in Gulf Countries: a narrative review and insights from the Gulf multiple myeloma experts. Curr Med Res Opin. 2025;41(4):593\u2013600. https:\/\/doi.org\/10.1080\/03007995.2025.2502125.","journal-title":"Curr Med Res Opin"},{"key":"428_CR23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118185","author":"M Dag","year":"2018","unstructured":"Dag M, Beksac M. A cross sectional epidemiological and survival analysis of all patients with plasma cell disorders recorded between 2011-2017 in the social insurance system of Turkey. Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-99-118185.","journal-title":"Blood"},{"key":"428_CR24","unstructured":"SHC. Cancer incidence report Saudi Arabia 2022. In: Council SH, editor. 2022."},{"issue":"4","key":"428_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5144\/0256-4947.2021.198","volume":"41","author":"AK Abdrabou","year":"2021","unstructured":"Abdrabou AK, Al Sharif F, El Fakih R, Hashmi S, Khafaga YM, Alhayli S, et\u00a0al. Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ann Saudi Med. 2021;41(4):198\u2013205. https:\/\/doi.org\/10.5144\/0256-4947.2021.198.","journal-title":"Ann Saudi Med"},{"key":"428_CR26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110503","author":"A Alam","year":"2018","unstructured":"Alam A, Al Qawasmeh K, Aamir M, McCarthy PL. Multiple myeloma therapy in Tawam Hospital. First report from United Arab Emirates (UAE). Blood. 2018. https:\/\/doi.org\/10.1182\/blood-2018-99-110503.","journal-title":"Blood"},{"key":"428_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1547138","volume":"15","author":"A Alhejazi","year":"2025","unstructured":"Alhejazi A, Alhuraiji A, Nourallah A, Alshehri A, Usman B, ElGohary G, et\u00a0al. Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study). Front Oncol. 2025;15:1547138.","journal-title":"Front Oncol"},{"key":"428_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/HS9.0000000000000404","volume":"4","author":"M Althomali","year":"2020","unstructured":"Althomali M, Mutahar E, Al Hashmi H, Alhejazi A, Al Hazmi M, Al Saeed A, et\u00a0al. Efficacy and safety of daratumumab in the treatment of relapsed\/ refractory multiple myeloma, local experience from Saudi Arabia. HemaSphere. 2020;4:945. https:\/\/doi.org\/10.1097\/HS9.0000000000000404.","journal-title":"HemaSphere"},{"issue":"1","key":"428_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62885-0","volume":"10","author":"M Baysal","year":"2020","unstructured":"Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et\u00a0al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep. 2020;10(1):5991. https:\/\/doi.org\/10.1038\/s41598-020-62885-0.","journal-title":"Sci Rep"},{"issue":"4","key":"428_CR30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12288-019-01108-7","volume":"35","author":"R Ciftciler","year":"2019","unstructured":"Ciftciler R, Goker H, Buyukas\u0131k Y, Aladag E, Demiroglu H. Impact of pre-transplant and post-transplant remission status of patients on survival in newly diagnosed multiple myeloma. Indian J Hematol Blood Transfus. 2019;35(4):655\u201361. https:\/\/doi.org\/10.1007\/s12288-019-01108-7.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"428_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4274\/tjh.galenos.2019.2019.0061","volume":"37","author":"R \u00c7ift\u00e7iler","year":"2020","unstructured":"\u00c7ift\u00e7iler R, G\u00f6ker H, Demiro\u011flu H, Aksu S, Say\u0131nalp N, Haznedaro\u011flu \u0130C, et\u00a0al. Evaluation of the survival outcomes of multiple myeloma patients according to their plasmacytoma presentation at diagnosis. Turk J Hematol. 2020;37(4):256\u201362. https:\/\/doi.org\/10.4274\/tjh.galenos.2019.2019.0061.","journal-title":"Turk J Hematol"},{"issue":"5","key":"428_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15050633","volume":"15","author":"V Gursoy","year":"2025","unstructured":"Gursoy V, Baysal M, Sadri S, Hunutlu FC, Ersal T, Gul OO, et\u00a0al. Comparative analysis and validation of the IMPEDED VTE, IMPEDE VTE, and SAVED risk models in predicting venous thromboembolism in multiple myeloma patients: a retrospective study in T\u00fcrkiye. Diagnostics. 2025;15(5):633. https:\/\/doi.org\/10.3390\/diagnostics15050633.","journal-title":"Diagnostics"},{"issue":"3","key":"428_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.18502\/acta.v61i3.12737","volume":"61","author":"NM Kassem","year":"2023","unstructured":"Kassem NM, Saadeldin I, Zawam H, Kassem HA. Clinical significance of serum biomarkers: vascular endothelial growth factor-a and chemokine (c-x-c motif) ligand 13 in Egyptian multiple myeloma patients. Acta Med Iran. 2023;61(3):150\u201360. https:\/\/doi.org\/10.18502\/acta.v61i3.12737.","journal-title":"Acta Med Iran"},{"key":"428_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051014","author":"MA Kazg\u0131","year":"2024","unstructured":"Kazg\u0131 MA, Bayram E, Kosec\u0131 T, Mete B, Toyran T, Ergin M, et\u00a0al. Exploring the impact of cytogenetic abnormalities on treatment responses and survival outcomes in multiple myeloma: a single-centre experience of 13 years of follow-up. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12051014.","journal-title":"Biomedicines"},{"issue":"Suppl 1","key":"428_CR35","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.4103\/sjkdt.sjkdt_333_22","volume":"34","author":"MA Morad","year":"2023","unstructured":"Morad MA, Fahmy O, Marie MA, Samir E, Abdullah REE. Comparison of renal function before and after autologous stem cell transplantation in Egyptian patients with multiple myeloma and renal insufficiency: a retrospective study. Saudi J Kidney Dis Transpl. 2023;34(Suppl 1):S14-s23. https:\/\/doi.org\/10.4103\/sjkdt.sjkdt_333_22.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"428_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.09.026","volume":"45","author":"O Pektas","year":"2023","unstructured":"Pektas O, Navaratnam P, Rajput T, Fr\u0131edman HS, Dem\u0131rk\u0131r E, Tekle C, et\u00a0al. Real-world (RW) treatment patterns and outcomes in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) with at least one prior therapy in Turkey. Hematol Transfus Cell Ther. 2023;45:S15. https:\/\/doi.org\/10.1016\/j.htct.2023.09.026.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"4","key":"428_CR37","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4103\/ijpc.Ijpc_233_19","volume":"26","author":"NA Shaheen","year":"2020","unstructured":"Shaheen NA, Alqahtani M, Alawbthani NS, Thomas A, Alaskar A. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among multiple myeloma patients: a single-center experience. Indian J Palliat Care. 2020;26(4):506\u201311. https:\/\/doi.org\/10.4103\/ijpc.Ijpc_233_19.","journal-title":"Indian J Palliat Care"},{"issue":"4","key":"428_CR38","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3906\/sag-1712-160","volume":"48","author":"N Soyer","year":"2018","unstructured":"Soyer N, Pat\u0131r P, Uysal A, Duran M, \u00dcnal HD, Durusoy R, et\u00a0al. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/ refractory multiple myeloma: a real-life experience. Turk J Med Sci. 2018;48(4):777\u201385. https:\/\/doi.org\/10.3906\/sag-1712-160.","journal-title":"Turk J Med Sci"},{"issue":"2","key":"428_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11845-022-03014-w","volume":"192","author":"C Sulu","year":"2023","unstructured":"Sulu C, Yal\u0131n SF, G\u00fcrer T, Ar MC, Alt\u0131parmak MR. Renal recovery after acute kidney injury requiring urgent hemodialysis is not associated with improved survival of the patients with multiple myeloma. Ir J Med Sci. 2023;192(2):757\u201363. https:\/\/doi.org\/10.1007\/s11845-022-03014-w.","journal-title":"Ir J Med Sci"},{"issue":"4","key":"428_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4274\/tjh.galenos.2023.2023.0029","volume":"40","author":"A Tekinalp","year":"2023","unstructured":"Tekinalp A, Ged\u00fck A, Akdeniz A, Terzi Demirsoy ET, G\u00fcrsoy V, Aslaner Ak MA, et\u00a0al. Experience of daratumumab in relapsed\/refractory multiple myeloma: a multicenter study from T\u00fcrkiye. Turk J Hematol. 2023;40(4):242\u201350. https:\/\/doi.org\/10.4274\/tjh.galenos.2023.2023.0029.","journal-title":"Turk J Hematol"},{"issue":"3","key":"428_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4274\/tjh.2016.0397","volume":"34","author":"FF Yaln\u0131z","year":"2017","unstructured":"Yaln\u0131z FF, Akko\u00e7 N, Saliho\u011flu A, Ar MC, \u00d6ng\u00f6ren \u015e, E\u015fkazan AE, et\u00a0al. Clinical outcomes related to the use of bendamustine therapy for multiple myeloma patients relapsed\/refractory to immunomodulatory drugs and proteasome inhibitors. Turk J Hematol. 2017;34(3):233\u20138. https:\/\/doi.org\/10.4274\/tjh.2016.0397.","journal-title":"Turk J Hematol"},{"key":"428_CR42","doi-asserted-by":"publisher","DOI":"10.12659\/aot.947186","volume":"30","author":"U Y\u0131lmaz","year":"2025","unstructured":"Y\u0131lmaz U, Erdem Nurcan S, \u00d6zmen D, Saliho\u011flu A, E\u015fkazan AE, \u00d6ng\u00f6ren \u015e, et\u00a0al. Retrospective study to compare outcomes in 159 patients undergoing first autologous stem cell transplantation for myeloma treated with melphalan 140 mg\/m2 or 200 mg\/m2. Ann Transplant. 2025;30:e947186. https:\/\/doi.org\/10.12659\/aot.947186.","journal-title":"Ann Transplant"},{"issue":"2","key":"428_CR43","doi-asserted-by":"publisher","DOI":"10.46989\/001c.137860","volume":"7","author":"A Alhuraiji","year":"2025","unstructured":"Alhuraiji A, Al Farsi K, Mheidly K, Elsabah H, Cherif H, Hamad A, et\u00a0al. Relapsed\/refractory multiple myeloma: standard of care management of patients in the Gulf region. Clin Hematol Int. 2025;7(2):20.","journal-title":"Clin Hematol Int"},{"issue":"1","key":"428_CR44","doi-asserted-by":"publisher","DOI":"10.46989\/001c.128113","volume":"7","author":"M Marashi","year":"2025","unstructured":"Marashi M, Al Farsi K, Al Hateeti H, Alhuraiji A, Elsabah H, Cherif H, et\u00a0al. Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region. Clin Hematol Int. 2025;7(1):14.","journal-title":"Clin Hematol Int"},{"issue":"6","key":"428_CR45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.transci.2017.11.025","volume":"56","author":"E Tekg\u00fcnd\u00fcz","year":"2017","unstructured":"Tekg\u00fcnd\u00fcz E, Arat M, G\u00f6ker H, \u00d6zdo\u011fu H, Kaynar L, \u00c7a\u011f\u0131rgan S, et\u00a0al. Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: a position-statement from the Turkish Society of Apheresis (TSA). Transfus Apher Sci. 2017;56(6):845\u20139. https:\/\/doi.org\/10.1016\/j.transci.2017.11.025.","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"428_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.transci.2017.11.010","volume":"56","author":"E Tekg\u00fcnd\u00fcz","year":"2017","unstructured":"Tekg\u00fcnd\u00fcz E, Demirkan F, Vural F, G\u00f6ker H, \u00d6zdo\u011fu H, Kiki \u0130, et\u00a0al. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: the results of a survey from Turkish hematology research and education group (ThREG). Transfus Apher Sci. 2017;56(6):804\u20138. https:\/\/doi.org\/10.1016\/j.transci.2017.11.010.","journal-title":"Transfus Apher Sci"},{"key":"428_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.05.005","author":"A Alhejazi","year":"2025","unstructured":"Alhejazi A, Alotaibi GS, Saleh ASA, Alahmadi M, Motabi I, Alsharif FZ, et\u00a0al. Guidelines on management of multiple myeloma in the relapsed\/refractory setting: the Saudi Myeloma Working Group guideline. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.05.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.005","author":"GS Alotaibi","year":"2025","unstructured":"Alotaibi GS, Saleh ASA, Alhejazi A, Alahmadi M, Motabi I, Alsharif FZ, et\u00a0al. Definition, diagnosis, risk stratification and management of newly diagnosed multiple myeloma: the Saudi myeloma working group guidelines. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.06.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR49","unstructured":"Beksac M, Saliho\u011flu A, Seval GC: Multipl Miyelom Tan\u0131 ve Tedavi K\u0131lavuzu G\u00fcncelleme. 2024. https:\/\/www.thd.org.tr\/durum\/0. Accessed 11 Nov 2025."},{"issue":"3","key":"428_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4274\/tjh.galenos.2021.2020.0555","volume":"38","author":"S Mersin","year":"2021","unstructured":"Mersin S, Ged\u00fck A, Mehtap \u00d6, Tarkun P, \u00dcnal S, Polat MG, et\u00a0al. Evaluation of a generic bortezomib molecule in newly diagnosed multiple myeloma patients. Turk J Hematol. 2021;38(3):211\u20137. https:\/\/doi.org\/10.4274\/tjh.galenos.2021.2020.0555.","journal-title":"Turk J Hematol"},{"key":"428_CR51","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/jbm.S380133","volume":"13","author":"P Kaloyannidis","year":"2022","unstructured":"Kaloyannidis P, Abdulla F, Mutahar E, Al Hashim H, Al Harbi S, Estanislao A, et\u00a0al. Risk assessment for newly diagnosed fit young patients with multiple myeloma in the era of novel treatment modalities: should there be additional factors taken into consideration?? J Blood Med. 2022;13:619\u201330. https:\/\/doi.org\/10.2147\/jbm.S380133.","journal-title":"J Blood Med"},{"issue":"3","key":"428_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/hematolrep15030048","volume":"15","author":"\u0130H A\u00e7ar","year":"2023","unstructured":"A\u00e7ar \u0130H, G\u00fcven\u00e7 B. Efficacy of bendamustine, pomalidomide, and dexamethasone (BPD) regimen in relapsed\/refractory extramedullary myeloma: a retrospective single-centre study, real-life experience. Hematol Rep. 2023;15(3):465\u201373.","journal-title":"Hematol Rep"},{"issue":"6","key":"428_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/1120009x.2023.2208439","volume":"35","author":"M Bak\u0131rta\u015f","year":"2023","unstructured":"Bak\u0131rta\u015f M, Dal MS, Yi\u011feno\u011flu TN, Giden AO, Serin I, Ba\u015fc\u0131 S, et\u00a0al. Real-world data on the effectiveness and safety of ixazomib-lenalidomide-dexamethasone therapy in relapsed\/refractory multiple myeloma patients: a multicenter experience in Turkey. J Chemother. 2023;35(6):563\u20139. https:\/\/doi.org\/10.1080\/1120009x.2023.2208439.","journal-title":"J Chemother"},{"issue":"8","key":"428_CR54","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/j.clml.2020.02.017","volume":"20","author":"M Beksac","year":"2020","unstructured":"Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, et\u00a0al. Early access program results from Turkey and a literature review on daratumumab monotherapy among heavily pretreated patients with relapsed\/refractory myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(8):e474\u201384. https:\/\/doi.org\/10.1016\/j.clml.2020.02.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR55","unstructured":"Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, et\u00a0al. Multicenter early access program results from Turkey: efficacy and safety of daratumumab among heavily pretreated relapse\/refractory multiple myeloma patients. Blood. 2017;130."},{"issue":"3","key":"428_CR56","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/j.clml.2022.12.007","volume":"23","author":"M Beksac","year":"2023","unstructured":"Beksac M, Seval GC, Koyun D, Topcuoglu P, Yuksel MK, Gurman G, et\u00a0al. Generic lenalidomide Rivelime versus brand-name Revlimid\u00ae in the treatment of relapsed\/refractory multiple myeloma: a retrospective single-center experience on efficacy, safety and survival outcome. Clin Lymphoma Myeloma Leuk. 2023;23(3):e164\u201370. https:\/\/doi.org\/10.1016\/j.clml.2022.12.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"428_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4274\/tjh.galenos.2020.2020.0169","volume":"38","author":"AZ Bolaman","year":"2021","unstructured":"Bolaman AZ, Turgutkaya A, Sahip B, Selim C, Ero\u011flu K\u00fc\u00e7\u00fckerdiler H, Ertop \u015e, et\u00a0al. Original versus generic lenalidomide in patients with relapsed\/refractory multiple myeloma: comparison of efficacy and adverse events. Turk J Hematol. 2021;38(1):41\u20138. https:\/\/doi.org\/10.4274\/tjh.galenos.2020.2020.0169.","journal-title":"Turk J Hematol"},{"key":"428_CR58","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1182\/blood-2019-131093","volume":"134","author":"Z Bolaman","year":"2019","unstructured":"Bolaman Z, Ertop S, Turgutkaya A, Cem S, Eroglu Kucukerdiler AH, Sahip B, et\u00a0al. Original versus generic lenalidomide in patients with relapsed multipl myeloma: comparison of effectivity and adverse events. Blood. 2019;134:5594. https:\/\/doi.org\/10.1182\/blood-2019-131093.","journal-title":"Blood"},{"key":"428_CR59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131093","author":"GH Ozsan","year":"2017","unstructured":"Ozsan GH, Sevindik OG, Sadri S, Hacioglu SK, Kaya SY, Geduk A, et\u00a0al. Real-world data in relapsed refractory myeloma patients treated with pomalidomide, a multicenter Turkish experience. Blood. 2017. https:\/\/doi.org\/10.1182\/blood-2019-131093.","journal-title":"Blood"},{"key":"428_CR60","first-page":"784","volume":"102","author":"G Saydam","year":"2017","unstructured":"Saydam G, Soyer N, Patir P, Uysal A, Duran M, Durusoy R, et\u00a0al. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma: a real life experience from Turkey. Haematologica. 2017;102:784.","journal-title":"Haematologica"},{"key":"428_CR61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.5405.5405","author":"OG Sevindik","year":"2017","unstructured":"Sevindik OG, Pehlivan M, Tuglular TF, Solmaz SM, Dogu MH, Yalniz F, et\u00a0al. Real-world data in relapsed refractory myeloma patients treated with carfilzomib, a multicenter Turkish experience. Blood. 2017. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.5405.5405.","journal-title":"Blood"},{"key":"428_CR62","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1002\/ajh.25639","volume":"94","author":"M Beksac","year":"2019","unstructured":"Beksac M, Seval GC, Koyun D, Topcuoglu P, Yuksel MK, Gurman G, et\u00a0al. A retrospective single center experience with the generic of lenalidomide Rivelime\u00ae compared with original patented drug Revlimid\u00ae. Am J Hematol. 2019;94:S7. https:\/\/doi.org\/10.1002\/ajh.25639.","journal-title":"Am J Hematol"},{"issue":"3","key":"428_CR63","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.7314\/apjcp.2016.17.3.1351","volume":"17","author":"IA Abdelgawad","year":"2016","unstructured":"Abdelgawad IA, Radwan NH, Shafik RE, Shokralla HA. Significance of proliferation markers and prognostic factors in Egyptian patients with multiple myeloma. Asian Pac J Cancer Prev. 2016;17(3):1351\u20135. https:\/\/doi.org\/10.7314\/apjcp.2016.17.3.1351.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"428_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5144\/0256-4947.2024.93","volume":"44","author":"AK Abdrabou","year":"2024","unstructured":"Abdrabou AK, Al Sharif F, El Fakih R, Zahrani HA, Al Yamany R, Saleh M, et\u00a0al. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients. Ann Saudi Med. 2024;44(2):93\u2013103. https:\/\/doi.org\/10.5144\/0256-4947.2024.93.","journal-title":"Ann Saudi Med"},{"issue":"1","key":"428_CR65","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2020.8267","volume":"12","author":"R Ciftciler","year":"2020","unstructured":"Ciftciler R, Goker H, Buyukasik Y, Say\u0131nalp N, Haznedaroglu IC, Aksu S, et\u00a0al. Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematol Rep. 2020;12(1):8267. https:\/\/doi.org\/10.4081\/hr.2020.8267.","journal-title":"Hematol Rep"},{"key":"428_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30957-5","volume":"20","author":"M Denewer","year":"2020","unstructured":"Denewer M, Shamaa S, Samra M, El-Nahass YEN, Azmy E. MM-375: prognostic impact of multiple myeloma cytogenetic abnormalities on outcome of autologous bone marrow transplantation: a single-center experience. Clin Lymphoma Myeloma Leuk. 2020;20:S309. https:\/\/doi.org\/10.1016\/S2152-2650(20)30957-5.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"428_CR67","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00277-016-2692-0","volume":"95","author":"AM El-Ghammaz","year":"2016","unstructured":"El-Ghammaz AM, Abdelwahed E. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and\/or t(4;14) and overcomes their adverse prognosis. Ann Hematol. 2016;95(8):1315\u201321. https:\/\/doi.org\/10.1007\/s00277-016-2692-0.","journal-title":"Ann Hematol"},{"issue":"14","key":"428_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144142","volume":"13","author":"E Erdogan Yucel","year":"2024","unstructured":"Erdogan Yucel E, Kirmaz AT, Kakci M, Yavuz AF, Sencelikel T, Alacacioglu I, et\u00a0al. The effect of age on high-dose therapy with autologous stem cell support in multiple myeloma: a single-center experience. J Clin Med. 2024;13(14):4142.","journal-title":"J Clin Med"},{"issue":"1","key":"428_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-020-05392-9","volume":"13","author":"MP Kirik","year":"2020","unstructured":"Kirik MP, Pehlivan M, Nursal AF, Oyaci Y, Pehlivan S, Serin I. The\u00a0miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with\u00a0multiple myeloma. BMC Res Notes. 2020;13(1):545. https:\/\/doi.org\/10.1186\/s13104-020-05392-9.","journal-title":"BMC Res Notes"},{"issue":"12","key":"428_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/17474086.2021.1962279","volume":"14","author":"T \u015eahin","year":"2021","unstructured":"\u015eahin T, Turgutkaya A, Kad\u0131k\u00f6yl\u00fc G, Bolaman AZ, Yava\u015fo\u011flu \u0130. Investigation of demographic features, performance, comorbidity status and mortality causes among multiple myeloma patients: real-life data. Expert Rev Hematol. 2021;14(12):1147\u201353. https:\/\/doi.org\/10.1080\/17474086.2021.1962279.","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"428_CR71","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/j.clml.2019.09.402","volume":"19","author":"M Beksac","year":"2019","unstructured":"Beksac M, Seval GC, Paydas S, Tuglular TF, Arslan O, Goker H, et\u00a0al. Elotuzumab plus pomalidomide or lenalidomide is able to achieve durable \u2265VGPR responses among immunomodulatory \/ proteasome inhibitor refractory myeloma patients: a report on multicenter experience from Turkey. Clin Lymphoma Myeloma Leuk. 2019;19(10):e242\u20133. https:\/\/doi.org\/10.1016\/j.clml.2019.09.402.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148835","volume":"138","author":"G Cengiz","year":"2021","unstructured":"Cengiz G, Karakaya B, Yilmaz H, Koyun D, Kircali E, Basboga S, et\u00a0al. Comparison of salvage autologous hematopoietic cell transplantation with outcomes following selinexor combinations among double\/triple refractory myeloma patients. Blood. 2021;138:4904. https:\/\/doi.org\/10.1182\/blood-2021-148835.","journal-title":"Blood"},{"issue":"2","key":"428_CR73","first-page":"95","volume":"5","author":"MC Ozkan","year":"2015","unstructured":"Ozkan MC, Tombuloglu M, Sahin F, Saydam G. Evaluation of immunomodulatory drugs in multiple myeloma: single center experience. Am J Blood Res. 2015;5(2):95\u2013100.","journal-title":"Am J Blood Res"},{"key":"428_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03972-8","author":"K Kim","year":"2025","unstructured":"Kim K, Verburgh E, Mitina T, Chen W, Yeh SP, Schutz N, et\u00a0al. Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: the INTEGRATE study. Int J Hematol. 2025. https:\/\/doi.org\/10.1007\/s12185-025-03972-8.","journal-title":"Int J Hematol"},{"issue":"1","key":"428_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1078155219835303","volume":"26","author":"EG Um\u0131t","year":"2020","unstructured":"Um\u0131t EG, Baysal M, Bas V, Asker I, K\u0131rk\u0131zlar O, Dem\u0131r AM. Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy. J Oncol Pharm Pract. 2020;26(1):43\u201350. https:\/\/doi.org\/10.1177\/1078155219835303.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"428_CR76","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/j.pmn.2024.05.006","volume":"25","author":"Y Karacan","year":"2024","unstructured":"Karacan Y, Akkus Y, Bayram R, Budak S, \u00dcnl\u00fc AA. Do spiritual well-being and pain intensity predict physical or mental components of health-related quality-of-life scale in patients with multiple myeloma? Pain Manag Nurs. 2024;25(5):e367\u201374. https:\/\/doi.org\/10.1016\/j.pmn.2024.05.006.","journal-title":"Pain Manag Nurs"},{"issue":"8","key":"428_CR77","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00590-020-02721-3","volume":"30","author":"SB Tekin","year":"2020","unstructured":"Tekin SB, Karsl\u0131 B, B\u00fcy\u00fckbebeci O, Demir \u0130H, G\u00f6kalp AY, K\u0131l\u0131n\u00e7o\u011flu V. How do vertebroplasty and kyphoplasty affect the quality of life of patients with multiple myeloma spinal metastasis? Eur J Orthop Surg Traumatol. 2020;30(8):1447\u201351. https:\/\/doi.org\/10.1007\/s00590-020-02721-3.","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"2","key":"428_CR78","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5152\/j.aott.2021.20130","volume":"55","author":"OM Topkar","year":"2021","unstructured":"Topkar OM, Erol B. Clinical outcomes and complications of surgical interventions for multiple myeloma lesions in the extremities and pelvis: a retrospective clinical study. Acta Orthop Traumatol Turc. 2021;55(2):159\u201365. https:\/\/doi.org\/10.5152\/j.aott.2021.20130.","journal-title":"Acta Orthop Traumatol Turc"},{"key":"428_CR79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2014.118075","volume":"100","author":"B Ate\u015fa\u0287a\u0287lu","year":"2015","unstructured":"Ate\u015fa\u0287a\u0287lu B, Topc\u00b8uo\u0287lu P, Merter M, Sungurlu M, \u015eener \u00d6, Beksac\u00b8 M. Subcutaneous bortezomib is as effective and less neurotoxic than intravenous bortezomib: Ankara university experience. Haematologica. 2015;100:740\u20131.","journal-title":"Haematologica"},{"issue":"4","key":"428_CR80","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1078155217697486","volume":"24","author":"E Aypar","year":"2018","unstructured":"Aypar E, \u0130zzettin FV, Ak\u0131 \u015eZ, Sancar M, Ye\u011fin ZA, T\u00fcrk\u00f6z-Sucak G. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: high-dose melphalan versus high-dose melphalan and bortezomib. J Oncol Pharm Pract. 2018;24(4):281\u20139. https:\/\/doi.org\/10.1177\/1078155217697486.","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"428_CR81","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1177\/10781552221132554","volume":"29","author":"AN Kul","year":"2023","unstructured":"Kul AN, Ipek Y. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics. J Oncol Pharm Pract. 2023;29(7):1652\u201360. https:\/\/doi.org\/10.1177\/10781552221132554.","journal-title":"J Oncol Pharm Pract"},{"key":"428_CR82","doi-asserted-by":"publisher","first-page":"S440","DOI":"10.1038\/bmt.2015.30","volume":"50","author":"P Topcuoglu","year":"2015","unstructured":"Topcuoglu P, Gultay D, Ozturk N, Kilic O, Okay M, Eraslan Karadag Y, et\u00a0al. Generic (Bioequivalent) melphalan has similar efficacy and toxicity but lower cost in the conditioning regimen for autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:S440. https:\/\/doi.org\/10.1038\/bmt.2015.30.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"428_CR83","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.jval.2023.09.527","volume":"26","author":"G Elsisi","year":"2023","unstructured":"Elsisi G, Elattar M, Eldesouky N. EE260 cost-effectiveness analysis of daratumumab triplet therapy vs carfilzomib duplet therapy in patients with relapsed or refractory multiple myeloma in Egypt from payer perspective. Value Health. 2023;26(12):S101. https:\/\/doi.org\/10.1016\/j.jval.2023.09.527.","journal-title":"Value Health"},{"issue":"10","key":"428_CR84","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1080\/13696998.2020.1796288","volume":"23","author":"GH Elsisi","year":"2020","unstructured":"Elsisi GH, Carapinha JL, Afify R, Elmoty MA, Khalaf M. A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients. J Med Econ. 2020;23(10):1168\u201375. https:\/\/doi.org\/10.1080\/13696998.2020.1796288.","journal-title":"J Med Econ"},{"key":"428_CR85","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jval.2024.10.462","volume":"27","author":"M Farghaly","year":"2024","unstructured":"Farghaly M, Fasseeh A, Korra N, Abd-El Aziz A, Al Dallal S, Badr M, et\u00a0al. EE178 the burden of multiple myeloma in the Gulf Region. Value Health. 2024;27:S88. https:\/\/doi.org\/10.1016\/j.jval.2024.10.462.","journal-title":"Value Health"},{"issue":"2","key":"428_CR86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.36469\/001c.120288","volume":"11","author":"A Hamad","year":"2024","unstructured":"Hamad A, Elazzazy S, Taha RY, Osman H, Blooshi S, Elkonaissi I, et\u00a0al. Cost-minimization analysis for subcutaneous daratumumab in the treatment of newly diagnosed multiple myeloma in 3 Gulf countries. J Health Econ Outcome Res. 2024;11(2):9\u201319. https:\/\/doi.org\/10.36469\/001c.120288.","journal-title":"J Health Econ Outcome Res"},{"key":"428_CR87","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/j.jval.2019.09.411","volume":"22","author":"R Maroun","year":"2019","unstructured":"Maroun R, Kilic E, Dokuyucu O, Coggia A. PCN215 cost comparison of lenalidomide based triple combination therapies for the treatment of relapsed\/refractory multiple myeloma in the Kingdom of Saudi Arabia. Value Health. 2019;22:S477. https:\/\/doi.org\/10.1016\/j.jval.2019.09.411.","journal-title":"Value Health"},{"key":"428_CR88","doi-asserted-by":"crossref","unstructured":"Eser S, \u00d6r\u00fcn H, Hamavio\u011flu E, Lofti F. Cancer incidence, mortality and survival in T\u00fcrkiye as of 2020. Basic Clin Cancer Res. 2022.","DOI":"10.18502\/bccr.v14i1.14383"},{"issue":"1","key":"428_CR89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ijc.31664","volume":"144","author":"S Pilleron","year":"2019","unstructured":"Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, et\u00a0al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49\u201358. https:\/\/doi.org\/10.1002\/ijc.31664.","journal-title":"Int J Cancer"},{"issue":"4","key":"428_CR90","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/j.clml.2021.10.001","volume":"22","author":"EM Ocio","year":"2022","unstructured":"Ocio EM, Montes-Gais\u00e1n C, Bustamante G, Garz\u00f3n S, Gonz\u00e1lez E, P\u00e9rez E, et\u00a0al. Clinical and sociodemographic characteristics of patients with relapsed and\/or refractory multiple myeloma and their influence on treatment in the real-world setting in Spain: the CharisMMa study. Clin Lymphoma Myeloma Leuk. 2022;22(4):e241\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"428_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09980-9","volume":"22","author":"R Medhekar","year":"2022","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22(1):901.","journal-title":"BMC Cancer"},{"issue":"4","key":"428_CR92","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","volume":"98","author":"VT Hungria","year":"2019","unstructured":"Hungria VT, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, et\u00a0al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941\u20139.","journal-title":"Ann Hematol"},{"key":"428_CR93","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00400-z","author":"CM Seehaus","year":"2025","unstructured":"Seehaus CM, Remaggi G, Filho JS, Ochoa P, Bigni R, de Magalh\u00e3es RJP, et\u00a0al. Burden of treatment, treatment sequencing and healthcare resource utilization in multiple myeloma in Latin America: a targeted literature review. Oncol Ther. 2025. https:\/\/doi.org\/10.1007\/s40487-025-00400-z.","journal-title":"Oncol Ther"},{"key":"428_CR94","unstructured":"\u0130P: KISA \u00dcR\u00dcN B\u0130LG\u0130S\u0130. 2022. https:\/\/pdf.ilacprospektusu.com\/21355-darzalex-1800-mg-sc-enjeksiyonluk-cozelti-kub.pdf. Accessed 29 Nov 2025."},{"issue":"22","key":"428_CR95","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2217\/fon-2023-0020","volume":"19","author":"A Ribbands","year":"2023","unstructured":"Ribbands A, Boytsov N, Bailey A, Gorsh B, Luke E, Lambert A. Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA. Future Oncol. 2023;19(22):1549\u201362.","journal-title":"Future Oncol"},{"issue":"9","key":"428_CR96","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinska JM, Nelson JJ, Lunacsek OE, Stafkey-Mailey DR, et\u00a0al. Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017\u201325.","journal-title":"Expert Rev Hematol"},{"issue":"14","key":"428_CR97","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","volume":"30","author":"K Natrajan","year":"2024","unstructured":"Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR. FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(14):2865\u201371.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"428_CR98","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1158\/1078-0432.Ccr-24-4181","volume":"31","author":"P Sharma","year":"2025","unstructured":"Sharma P, Lin X, Xu Z, Kanapuru B, Theoret MR, Sokolic R, et\u00a0al. FDA approval summary: idecabtagene vicleucel for the treatment of triple-class-exposed, relapsed or refractory multiple myeloma. Clin Cancer Res. 2025;31(16):3362\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-4181.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"428_CR99","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1158\/1078-0432.Ccr-24-1872","volume":"30","author":"AC Baines","year":"2024","unstructured":"Baines AC, Kanapuru B, Zhao J, Price LSL, Zheng N, Konicki R, et\u00a0al. FDA approval summary: teclistamab-a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(24):5515\u201320. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1872.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"428_CR100","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/2643-3230.Bcd-23-0176","volume":"4","author":"R Firestone","year":"2023","unstructured":"Firestone R, Lesokhin AM, Usmani SZ. An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma. Blood Cancer Discov. 2023;4(6):433\u20136. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-23-0176.","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"428_CR101","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/j.jtct.2023.12.523","volume":"30","author":"R Atallah","year":"2024","unstructured":"Atallah R, Shatnawi Y, Mammadzadeh A, Hashmi SK, Shabeeha R, Mushtaq MU, et\u00a0al. The GLAMM1 study\u2014global access to myeloma medications: potential barriers to chimeric antigen receptors (CART) and t-cell-engaging bispecific antibodies (TCE) globally. Transplant Cell Ther. 2024;30(2):S373\u20134. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.523.","journal-title":"Transplant Cell Ther"},{"key":"428_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1413825","author":"G Hakan","year":"2024","unstructured":"Hakan G, Engin K, Elifcan KA, Haluk D, Mehmet T, Suman K, et\u00a0al. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2024.1413825.","journal-title":"Front Med"},{"issue":"7","key":"428_CR103","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","volume":"30","author":"M Markouli","year":"2023","unstructured":"Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M, et\u00a0al. Toxicity profile of chimeric antigen receptor t-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management. Curr Oncol. 2023;30(7):6330\u201352. https:\/\/doi.org\/10.3390\/curroncol30070467.","journal-title":"Curr Oncol"},{"key":"428_CR104","unstructured":"Mayo stratification for myeloma and risk-adapted therapy. Newly diagnosed myeloma. 2024. https:\/\/static1.squarespace.com\/static\/5b44f08ac258b493a25098a3\/t\/674ddeb4676dad6c868c9c55\/1733156532740\/mSMART+Newly+Dx+v22+Oct+2024rev3.pdf. Accessed 29 Aug 2025."},{"issue":"9","key":"428_CR105","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos M-V, Zweegman S, et\u00a0al. EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680\u2013700. https:\/\/doi.org\/10.1038\/s41571-025-01041-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"428_CR106","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","volume":"96","author":"VT Hungria","year":"2017","unstructured":"Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L, et\u00a0al. Observational study of multiple myeloma in Latin America. Ann Hematol. 2017;96(1):65\u201372. https:\/\/doi.org\/10.1007\/s00277-016-2866-9.","journal-title":"Ann Hematol"},{"issue":"4","key":"428_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.144582","volume":"7","author":"J Almasri","year":"2025","unstructured":"Almasri J, Hasan B, Tarakji Z, Naffa FW, Warner L, Mian H, et\u00a0al. Treatment outcomes of multiple myeloma in developing countries: a systematic review and meta-analysis. Clin Hematol Int. 2025;7(4):1.","journal-title":"Clin Hematol Int"},{"issue":"6","key":"428_CR108","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clml.2023.03.005","volume":"23","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Tran D, Laidlaw A, Rosta E, Rai M, Duran J, et\u00a0al. Impact of disease progression, line of therapy, and response on health-related quality of life in multiple myeloma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2023;23(6):426-37.e11. https:\/\/doi.org\/10.1016\/j.clml.2023.03.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR109","doi-asserted-by":"publisher","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235. https:\/\/doi.org\/10.1177\/1178224219868235.","journal-title":"Palliat Care Soc Pract"},{"issue":"3","key":"428_CR110","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","volume":"97","author":"X Leleu","year":"2018","unstructured":"Leleu X, Gay F, Flament A, Allcott K, Delforge M. Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? Ann Hematol. 2018;97(3):387\u2013400.","journal-title":"Ann Hematol"},{"issue":"3","key":"428_CR111","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1574886318666230817162424","volume":"19","author":"PL de Miranda Drummond","year":"2024","unstructured":"de Miranda Drummond PL, Dos Santos RMM, Silveira LP, Malta JS, Moreira Reis AM, Costa NL, et\u00a0al. Chemotherapy-induced peripheral neuropathy impacts quality of life and activities of daily living of Brazilian multiple myeloma patients. Curr Drug Saf. 2024;19(3):356\u201367.","journal-title":"Curr Drug Saf"},{"issue":"8","key":"428_CR112","first-page":"917","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, Boytsov N, Carlson JJ, Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29(8):917\u201326.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"428_CR113","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.clml.2024.04.004","volume":"24","author":"C Bennink","year":"2024","unstructured":"Bennink C, Brink M, Duijts SF, Scheurer H, Sonneveld P, Blommestein HM. Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands. Clin Lymphoma Myeloma Leuk. 2024;24(9):604\u201310.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"428_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100243","volume":"17","author":"S Kolovos","year":"2019","unstructured":"Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, et\u00a0al. Unplanned admissions for patients with myeloma in the UK: low frequency but high costs. J Bone Oncol. 2019;17:100243.","journal-title":"J Bone Oncol"},{"issue":"1","key":"428_CR115","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","volume":"25","author":"M Choon-Quinones","year":"2022","unstructured":"Choon-Quinones M, Zelei T, Barnett M, Keown P, Durie B, Kal\u00f3 Z, et\u00a0al. Beyond medicines\u2019 barriers: exploring the true cost of multiple myeloma. J Med Econ. 2022;25(1):1167\u201375.","journal-title":"J Med Econ"},{"issue":"31","key":"428_CR116","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2023-0021","volume":"19","author":"J Mart\u00ednez-Lopez","year":"2023","unstructured":"Mart\u00ednez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, et\u00a0al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 2023;19(31):2103\u201321.","journal-title":"Future Oncol"},{"issue":"1","key":"428_CR117","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00277-023-05511-z","volume":"103","author":"B Bostankolu De\u011firmenci","year":"2024","unstructured":"Bostankolu De\u011firmenci B, Yegin ZA, Akdemir \u00dc, Dede A, G\u00fcndem GG, \u00d6zkurt ZN, et\u00a0al. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care. Ann Hematol. 2024;103(1):269\u201383. https:\/\/doi.org\/10.1007\/s00277-023-05511-z.","journal-title":"Ann Hematol"},{"issue":"1","key":"428_CR118","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4274\/tjh.galenos.2020.2020.0115","volume":"38","author":"R \u00c7ift\u00e7iler","year":"2021","unstructured":"\u00c7ift\u00e7iler R, G\u00f6ker H, Demiro\u011flu H, Haznedaro\u011flu \u0130C, Say\u0131nalp N, Aksu S, et\u00a0al. Evaluation of prognostic significance of the international staging system according to glomerular filtration rate in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation. Turk J Hematol. 2021;38(1):33\u201340. https:\/\/doi.org\/10.4274\/tjh.galenos.2020.2020.0115.","journal-title":"Turk J Hematol"},{"key":"428_CR119","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.1016\/S2152-2650(24)01641-0","volume":"24","author":"AR Elsergany","year":"2024","unstructured":"Elsergany AR, Shamaa S, Awad M, Ibrahim M, Elkhodary T, Abd Elhamid M, et\u00a0al. MM-095 Safety and efficacy of dexamethasone for prevention of engraftment syndrome in a patient with multiple myeloma undergoing ASCT: a single-center experience. Clin Lymphoma Myeloma Leuk. 2024;24:S535\u20136. https:\/\/doi.org\/10.1016\/S2152-2650(24)01641-0.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"428_CR120","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.3390\/curroncol30060423","volume":"30","author":"Y Ipek","year":"2023","unstructured":"Ipek Y, Karademir N, Yilmazer O, Yilmaz G. The effects of second primary malignancies and frailty on overall survival and mortality in geriatric Turkish patients with multiple myeloma. Curr Oncol. 2023;30(6):5615\u201330. https:\/\/doi.org\/10.3390\/curroncol30060423.","journal-title":"Curr Oncol"},{"issue":"1","key":"428_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s43046-020-00054-0","volume":"32","author":"NM Kassem","year":"2020","unstructured":"Kassem NM, Kassem HA, Ibrahim M, Zawam H, Hamada E. The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients. J Egypt Natl Canc Inst. 2020;32(1):43. https:\/\/doi.org\/10.1186\/s43046-020-00054-0.","journal-title":"J Egypt Natl Canc Inst"},{"key":"428_CR122","first-page":"S18","volume":"10","author":"O Khojah","year":"2019","unstructured":"Khojah O, Al-Majed M, Al-Mozain N, Al-Rajeh A, Al-Sharif F, Khalil S. Genetic characteristic of 123 newly diagnosed plasma cell myeloma patients: a 5 years\u2019 experience of a single oncology center. J Appl Hematol. 2019;10:S18\u20139.","journal-title":"J Appl Hematol"},{"key":"428_CR123","first-page":"S13","volume":"7","author":"O Khojah","year":"2016","unstructured":"Khojah O, Al-Rajeh A, Al-Majed M, Ramadan S, Al-Mozain N, Al-Sharif F, et\u00a0al. Molecular cytogenetic analysis of 103 newly diagnosed plasma cell myeloma patients resulting in a novel biphasic approach. J Appl Hematol. 2016;7:S13\u20134.","journal-title":"J Appl Hematol"},{"key":"428_CR124","volume":"38","author":"O Khojah","year":"2016","unstructured":"Khojah O, Barri S, Ramadan S, Al-Sharif F, Al-Maeen AR, Khalil S. A proposed biphasic approach based on analysis of genetic alteration in newly diagnosed plasma cell myeloma patients. Int J Lab Hematol. 2016;38:53.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"428_CR125","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1515\/med-2021-0216","volume":"16","author":"UY Malkan","year":"2021","unstructured":"Malkan UY, Demiroglu H, Buyukasik Y, Karatas A, Aladag E, Goker H. Comparison of single and double autologous stem cell transplantation in multiple myeloma patients. Open Med. 2021;16(1):192\u20137. https:\/\/doi.org\/10.1515\/med-2021-0216.","journal-title":"Open Med"},{"issue":"4","key":"428_CR126","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12288-015-0618-y","volume":"32","author":"B Onec","year":"2016","unstructured":"Onec B, Okutan H, Albayrak M, Can ES, Aslan V, Soyer Kosemehmetoglu O, et\u00a0al. Comparative evaluation of common comorbidity scores and Freiburger comorbidity index as prognostic variables in a real life multiple myeloma population. Indian J Hematol Blood Transfus. 2016;32(4):424\u201330. https:\/\/doi.org\/10.1007\/s12288-015-0618-y.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"12","key":"428_CR127","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4103\/njcp.njcp_107_24","volume":"27","author":"H \u00d6zt\u00fcrk","year":"2024","unstructured":"\u00d6zt\u00fcrk H, Dikyar A, Ye\u011fin Z, Kaynar L, Can F, \u00d6zkurt Z. Allogeneic hematopoietic stem cell transplantation in relapsed refractory multiple myeloma. Niger J Clin Pract. 2024;27(12):1405\u20139. https:\/\/doi.org\/10.4103\/njcp.njcp_107_24.","journal-title":"Niger J Clin Pract"},{"issue":"4","key":"428_CR128","doi-asserted-by":"publisher","first-page":"248","DOI":"10.18502\/ijhoscr.v14i4.4481","volume":"14","author":"A Y\u0131k\u0131lmaz","year":"2020","unstructured":"Y\u0131k\u0131lmaz A, Akinci S, Bakanay \u015eM, Dilek \u0130. VAD chemotherapy versus bortezomib containing regimens as remission induction for ASCT in multiple myeloma: a single center experience. Int J Hematol Oncol Stem Cell Res. 2020;14(4):248\u201356. https:\/\/doi.org\/10.18502\/ijhoscr.v14i4.4481.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"428_CR129","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.4103\/1658-5127.181113","volume":"7","author":"OZ Abduljalil","year":"2016","unstructured":"Abduljalil OZ, Al Hashmi HH. Retrospective observational study on multiple myeloma cases admitted to King Fahad Specialist Hospital: Dammam between 1st of June 2006 till the end of December 2013. J Appl Hematol. 2016;7:S17\u20138.","journal-title":"J Appl Hematol"},{"key":"428_CR130","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1097\/01.HS9.0000852292.38263.b8","volume":"6","author":"I Serin","year":"2022","unstructured":"Serin I, Oyaci Y, Pehlivan M, Pehlivan S. Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms. HemaSphere. 2022;6:3410\u20131. https:\/\/doi.org\/10.1097\/01.HS9.0000852292.38263.b8.","journal-title":"HemaSphere"},{"key":"428_CR131","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/01.HS9.0000567152.47204.3e","volume":"3","author":"GE Gmati","year":"2019","unstructured":"Gmati GE, Damlaj M, Alzaharani M, Altamimi S, Alherz N, Khalid F, et\u00a0al. Outcome of autologous stem cell transplantation in multiple myeloma; experience from a single center in Saudi Arabia. HemaSphere. 2019;3:973\u20134.","journal-title":"HemaSphere"},{"key":"428_CR132","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41409-018-0354-7","volume":"53","author":"S Amikishiyev","year":"2019","unstructured":"Amikishiyev S, Hindilerden IY, Erdem S, Aktan M, Nalcaci M, Sargin D, et\u00a0al. Infectious epidemiology in multiple myeloma patients after autologous stem cell transplantation: a single-center analysis from Turkey. Bone Marrow Transplant. 2019;53:566\u20137. https:\/\/doi.org\/10.1038\/s41409-018-0354-7.","journal-title":"Bone Marrow Transplant"},{"issue":"s1","key":"428_CR133","first-page":"734","volume":"100","author":"AT Firatli Tuglular","year":"2015","unstructured":"Firatli Tuglular AT, Pehlivan M, Sari HI, Ayyildiz MO, Saydam G, Sonmez M, et al. Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed\/refractory multiple myeloma: early safety report of Turkish pass study. Haematologica. 2015;100(s1):734.","journal-title":"Haematologica"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00428-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00428-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:35Z","timestamp":1782381215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00428-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00428-9","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meral Beksac: honoraria from BMS, Janssen; consulting or advisory role from GSK, Takeda, Amgen, Janssen, and Menarini. Hasan AAL Yaseen: received honoraria from GSK, Amgen, Novartis, and Abbvie. Guldane Cengi\u0307z Seval: honoraria from BMS, Janssen, Amgen, Menarini, Pfizer, Takeda, and Sanofi; consulting or advisory role from GSK, Janssen, Menarini, Pfizer, BMS, Takeda, and Sanofi. Ashraf Elghandour: received payment\/honoraria from J&J, AstraZeneca, Novartis, and Sanofi. Mahmoud Marashi: received payment for advisory board and lectures for Johnson & Johnson, Sanofi, Pfizer, Amgen, Abbvie, Eva Pharma, and Takeda. Bhumika Aggarwal, Jorge Mouro, Abhay Phansalkar: employees of GSK and hold financial equities in GSK. Mohamed Samra, Omar Abduljalil, Sevgi Besisik, Gamal Fathy, G\u00fcner Hayri \u00d6zsan, \u00d6m\u00fcr G\u00f6kmen Sevindik, and Ruba Yaseen Ibrahim Taha: none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}